VERO

Optimizing Health Care for Patients with Rheumatism

Rheumatoid arthritis (short: rheumatism) is one of the most common chronic inflammatory diseases. In Germany approximately 800.000 people suffer from rheumatism. Characteristic is an uncontrolled inflammation of the synovial membrane (synovitis), which if not treated does not only cause chronic pain but also a progressive deterioration of joints, together with loss of function and disablement.

The health care model “VERO” will contribute to optimize the use of pharmaceuticals especially in the high price range by providing patients with necessary pharmaceuticals and by avoiding an unnecessary or rather unnecessarily highly dosed use of pharmaceuticals. Another key area is to record the patients’ individual needs and to treat them appropriately in doctor-patient conversations. Through doctor-patient conversation it becomes possible to recognize pharmaceutical-related problems and to develop strategic solutions.

As a subproject manager, Prof. Dr. Tom Stargardt will be responsible for the health-economic evaluation of the project. As the evaluator, he works closely with the study center. He concretizes the evaluation design and does the data evaluation.